-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Buy on Sarepta Therapeutics, Lowers Price Target to $100

Benzinga·05/07/2025 16:55:43
Listen to the news
Goldman Sachs analyst Salveen Richter maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Buy and lowers the price target from $178 to $100.